Advertisement

Direct oral anticoagulants for extended-duration thromboprophylaxis in hospitalized medically ill patients: are we there yet?

  • Majed S. Al YamiEmail author
  • Osamah M. Alfayez
  • Sawsan M. Kurdi
  • Razan Alsheikh
Article

Abstract

Despite a recommended 7–10 days of thromboprophylaxis, medically ill patients remain at increased risk of developing venous thromboembolism (VTE) after hospital discharge. Here, we present a contemporary review on the efficacy and safety of extended-duration thromboprophylaxis with direct oral anticoagulants (DOACs) in hospitalized medically ill patients. A search of publication and trial databases of controlled trials conducted from 2010 to 2016 using the key terms apixaban, rivaroxaban, and betrixaban showed three phase III trials that met our search criteria. In the “ADOPT” trial, apixaban was not inferior to enoxaparin in preventing VTE events (relative risk [RR] of 0.87; 95% confidence interval [CI] 0.62–1.23; P = 0.44); however, major bleeding rate was significantly higher with apixaban (RR of 2.58; 95% CI 1.02–7.24; P = 0.04). In the “MAGELLAN” trial, rivaroxaban was superior to enoxaparin in preventing VTE events (RR of 0.77; 95% CI 0.62–0.96; P = 0.02) but with higher clinically relevant bleeding rate (RR of 2.5; 95% CI 1.85–3.25; P < 0.001). Finally, in the “APEX” trial, there were no differences between betrixaban and enoxaparin in preventing VTE events in patients with elevated D-dimer levels (RR of 0.81; 95% CI 0.65–1.00; P = 0.054) and no differences in major bleeding events in all patients (RR of 1.19; 95% CI 0.67–2.12; P = 0.55). Compared with standard-duration thromboprophylaxis with enoxaparin, extended-duration thromboprophylaxis with DOACs in medically ill patients may provide an incremental benefit, although at the cost of increased bleeding events.

Keywords

Apixaban Betrixaban Enoxaparin Rivaroxaban Thromboprophylaxis Medically Ill Patients 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animal performed by any of the authors.

References

  1. 1.
    Heit JA, Spencer FA, White RH (2016) The epidemiology of venous thromboembolism. J Thromb Thrombolysis 41(1):3–14. doi: 10.1007/s11239-015-1311-6 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH, American College of Chest Physicians (2012) Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e195S-226S. doi: 10.1378/chest.11-2296.Google Scholar
  3. 3.
    Amin AN, Varker H, Princic N, Lin J, Thompson S, Johnston S (2012) Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. J Hosp Med 7(3):231–238. doi: 10.1002/jhm.1002 CrossRefPubMedGoogle Scholar
  4. 4.
    Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI, ADOPT Trial Investigators (2011) Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 365(23):2167–2177. doi: 10.1056/NEJMoa1110899 CrossRefPubMedGoogle Scholar
  5. 5.
    Cohen AT, Spiro TE, Buller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V, MAGELLAN Investigators (2013) Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 368(6):513–523. doi: 10.1056/NEJMoa1111096 CrossRefPubMedGoogle Scholar
  6. 6.
    Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM, APEX Investigators (2016) Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med 375(6):534–544. doi: 10.1056/NEJMoa1601747 CrossRefPubMedGoogle Scholar
  7. 7.
    Cohen AT, Bailey CS, Alikhan R, Cooper DJ (2001) Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty—a meta-analysis. Thromb Haemost 85(5):940–941PubMedGoogle Scholar
  8. 8.
    Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT, Lassen MR (2012) Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br 94(2):257–264. doi: 10.1302/0301-620X.94B2.27850 CrossRefPubMedGoogle Scholar
  9. 9.
    Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Kakkar AK (2011) Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 105(3):444–453. doi: 10.1160/TH10-09-0601 CrossRefPubMedGoogle Scholar
  10. 10.
    Schulman S, Majeed A (2011) A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery. Drug Saf 34(6):449–463. doi: 10.2165/11587290-000000000-00000 CrossRefPubMedGoogle Scholar
  11. 11.
    Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, Vicaut E, Turpie AG, Yusen RD, study E (2010) Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med 153(1):8–18. doi: 10.7326/0003-4819-153-1-201007060-00004 CrossRefPubMedGoogle Scholar
  12. 12.
    Cohen AT, Halaby R, Korjian S, Daaboul Y, Szlosek D, Arbetter D, Goldhaber SZ, Hull R, Hernandez A, Gold A, Wiens B, Harrington R, Gibson CM (2016) The safety and efficacy of full versus reduced dose betrixaban in the acute medically Ill VTE (venous thromboembolism) prevention with extended duration betrixaban (APEX) trial. Am Heart J 185:93–100PubMedGoogle Scholar
  13. 13.
    Jain P, Szlosek DA, Korjian S, Daaboul Y, Lopes RD, Goldhaber SZ, Hernandez AF, Hull RD, Harrington RA, Cohen AT, Gibson CM (2016) Abstract 19325: betrixaban reduces the burden of multiple symptomatic venous thromboembolic events in the APEX trial. Circulation 134(Suppl 1):A19325Google Scholar
  14. 14.
    Gibson CM, Chi G, Halaby R, Korjian S, Daaboul Y, Jain P, Arbetter D, Goldhaber SZ, Hull R, Hernandez AF, Gold A, Bandman O, Harrington RA, Cohen AT, APEX Investigators (2016) Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically Ill patients: an APEX trial substudy (acute medically Ill venous thromboembolism prevention with extended duration betrixaban). Circulation. doi: 10.1161/CIRCULATIONAHA.116.025427 Google Scholar
  15. 15.
    Tao DL, Bien JY, DeLoughery TG, Shatzel JJ (2016) Extended thromboprophylaxis with direct oral anticoagulants for medical patients: A systematic review & meta-analysis. Blood. doi: 10.1182/blood-2016-10-747931 PubMedGoogle Scholar
  16. 16.
    Liew AY, Piran S, Eikelboom JW, Douketis JD (2016) Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials. J Thromb Thrombolysis. doi: 10.1007/s11239-016-1461-1 Google Scholar
  17. 17.
    Sqizzato A, Ageno W (2014) A new era for venous thromboembolism prevention in medical inpatients. Thromb Haemost 112:627–628CrossRefGoogle Scholar
  18. 18.
    Raskob GE, Spyropoulos AC, Zrubek J, Ageno W, Albers G, Elliott CG, Halperin J, Haskell L, Hiatt WR, Maynard GA, Peters G, Spiro T, Steg PG, Suh EY, Weitz JI (2016) The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost 115(5). doi: 10.1160/TH15-09-0756

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Majed S. Al Yami
    • 1
    • 2
    Email author
  • Osamah M. Alfayez
    • 1
    • 3
  • Sawsan M. Kurdi
    • 1
    • 4
  • Razan Alsheikh
    • 1
    • 5
  1. 1.Center for Health Outcomes and PharmacoEconomic ResearchUniversity of ArizonaTucsonUSA
  2. 2.King Saud bin Abdulaziz University for Health SciencesRiyadhSaudi Arabia
  3. 3.Qassim UniversityQassimSaudi Arabia
  4. 4.University of DammamDammamSaudi Arabia
  5. 5.King Abdulaziz UniversityJeddahSaudi Arabia

Personalised recommendations